Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant human endostatin continuous infusion system

A technology of continuous drug administration and vascular endothelium, applied in the direction of devices introduced into the body, pressure infusion, etc., can solve the problems of excessive fluctuations in blood drug concentration and the inability to maintain a steady-state concentration, improve patient compliance, and solve long-term problems. Obstacles, effects that increase purity

Inactive Publication Date: 2014-01-29
JIANGSU SIMCERE PHARMA
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Obviously, on the one hand, such a continuous infusion cycle of 14 days with a 7-day rest may cause excessive fluctuations in blood drug concentration in the body, making it impossible to maintain a steady-state concentration; on the other hand, such frequent injections, each The infusion time is 3 to 4 hours, which brings great pain to the patient physically and also brings great pressure to the patient psychologically, so that some patients give up the treatment halfway.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant human endostatin continuous infusion system
  • Recombinant human endostatin continuous infusion system
  • Recombinant human endostatin continuous infusion system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Pull out the needle plug of 2.5 Endostar syringes, fill the Endostar injection into the drug storage device of the Nipro pump, and then use the syringe to draw physiological saline to fill the drug storage device to replenish the drug solution to 240ml. Exhaust the air in the connecting tube, connect the intravenous indwelling catheter, fix it properly, set the parameters of the Nipro pump drive device to 2ml / hr, and pump Endostar into the patient at a loading dose of 0.3125mg / hr (7.5mg / day) for 120hr .

[0033]

Embodiment 2

[0035] Pull out the needle plugs of 5 Endostar syringes, fill the Endostar injection into the drug storage device of the Nipro pump, and then use the syringe to draw physiological saline to fill the drug storage device to replenish the drug solution to 240ml. Exhaust the air in the connecting tube, connect the intravenous indwelling catheter, fix it properly, set the parameters of the Nipro pump drive device to 2ml / hr, and pump Endostar into the patient at a loading dose of 0.625mg / hr (15mg / day) for 120hr.

[0036]

Embodiment 3

[0038] Pull out the needle plugs of 10 Endostar syringes, fill the Endostar injection into the drug storage device of the Baxter pump, and then use the syringe to draw physiological saline and fill the drug storage device to replenish the drug solution to 240ml. Exhaust the air in the connecting tube, connect the intravenous indwelling catheter, fix it properly, set the parameters of the Baxter pump drive device to 2ml / hr, and pump Endostar into the patient at a loading dose of 1.25mg / hr (30mg / day) for 120hr.

[0039]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of a recombinant human endostatin continuous intravenous infusion system which is high in purity, simple, convenient to use, and portable. The invention further provides a continuous infusion method of the infusion system. According to the recombinant human endostatin continuous infusion system, medicine infusion can be conducted continuously for days after one-time liquid injection, new impurities can not be generated, medicine purity can reach the standard of biological products, and then physiological pains of a patient are greatly reduced, and life quality of the patient is improved.

Description

technical field [0001] The invention relates to the technical field of a continuous intravenous administration system for recombinant human endostatin. Background technique [0002] In the 1960s, Dr. Folkman of Harvard Medical School put forward the hypothesis that "tumor growth depends on blood vessel growth", that is, angiogenesis plays an important role in the growth and metastasis of solid tumors, and in 1971 he proposed "starving tumors to death". therapy" theory. To stimulate angiogenesis, tumor cells upregulate a series of angiogenic factors and also produce some angiogenesis inhibitory factors. The opening and closing of angiogenic phenotypes in tissues will depend on the dynamic balance between stimulators and inhibitors of angiogenesis in local tissue regions (Folkman, J. Nat. MED. 1:27-31, 1995; Hanahan, D., et al. Cell. 86:353-364, 1996). Studies have found that endogenous angiogenesis inhibitors, such as angiotensin (Angiostatin), vascular endostatin (Endos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61M5/142
Inventor 岳德胜王鹏张弢王峰
Owner JIANGSU SIMCERE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com